Clinical Trials for Anxiety Disorders

Clinical Trials in Psychopharmacology: A Better Brain: Second Edition

Volumn , Issue , 2010, Pages 189-206

  Mula, Marco ^a,b   Strigaro, Gionata ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Anxiety disorders treatments drug therapies and cognitive behavioral therapies; Assessment of anxiety symptoms selection and classification of symptoms and or disorder and treatment evaluation; Clinical trials for anxiety disorders; Ethnicity, implications for drug metabolism and disposition; Generalized anxiety disorder (GAD); Methodological and design difficulties in field of psychiatric disorders; Panic disorder and drug therapies and cognitive behavioral therapies; Specific concerns addressed in designing clinical trials of psychotropic drugs; Treatment strategies for social anxiety disorder; Treatment produced change measurement

Indexed keywords

EID: 84877268909     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470749180.ch10     Document Type: Chapter

References (75)

1. Robins, L. and Regier, D.A. (1991) Psychiatric Disorder in America, Free Press, New York.
2. Bloom, F.E. and Kupfer, D.J. American College of Neuropsychopharmacology (1995) Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York.
3. Sheehan, D.V., Ballenger, J., and Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
4. Schweizer, E., Patterson, W., Rickels, K. et al. (1993) Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. The American Journal of Psychiatry, 150, 1210-1215.
5. Rickels, K., Schweizer, E., Csanalosi, I. et al. (1998) Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Archives of General Psychiatry, 45, 444-450.
6. Angst J., Vollrath M., Merikangas K.R., and Ernst C. (1990) Comorbidity of anxiety and depression in the Zurich cohort study of young adults, in Comorbidity of Mood and Anxiety Disorders (eds J.D. Maser and C.R. Cloninger), American Psychiatric Press, Washington, DC, pp. 123-137.
7. Kendall, P.C. and Flannery-Schroeder, E.C. (1998) Methodological issues in treatment research for anxiety disorders in youth. Journal of Abnormal Child Psychology, 26, 27-38.
8. Tanaka, E. (1998) In vivo age-related changes in hepatic drug-oxidizing capacity in humans. Journal of Clinical Pharmacology and Therapeutics, 23, 247-255.
9. Rudberg, I., Hendset, M., Uthus, L.H. et al. (2006) Heterozygous mutation in cytochrome P 2C19 significantly increases the concentration/dose ration of racemic citalopram and escitalopram (S-citalopram). Therapeutic Drug Monitoring, 28, 102-105.
10. Rudberg, I., Mohebi, B., Hermann, M. et al. (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical Pharmacology and Therapeutics, 83, 322-327.
11. Taylor, J.A. (1953) A personality scale of manifest anxiety. J Abnorm Psychol, 48, 285-290.
12. Hamilton, M. (1959) The assessment of anxiety states by rating. Br J Med Psychol, 32, 50-55.
13. Spielberger, C.D., Gorsuch, R.L., Lushene, R.E. (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto.
14. Spielberger, C.D. (1983) Manual for the State-Trait Anxiety Inventory. Revised Edition. Consulting Psychologists Press, Palo Alto.
15. Zung, W.W.K. (1971) A rating instrument for anxiety disorders. Psychosomatics, 12 (6), 371-379.
16. Schalling, D., Cronholm, B., Asberg, M. et al. (1973) Ratings of psychic and somatic anxiety indicants. Interrater reliability and relations to personality variables. Acta Psychiatr Scand, 49 (3), 353-368.
17. Wang, R.I., Wiesen, R.L., Treul, S. et al. (1976) A brief anxiety rating scale in evaluating anxiolytics. J Clin Pharmacol, 16 (2-3), 99-105.
18. Schwartz, G.E., Davidson, R.J., Goleman, D.J. (1978) Patterning of cognitive and somatic processes in the self-regulation of anxiety: effects of meditation versus exercise. Psychosom Med, 40 (4), 321-328.
19. Snaith, R.P., Baugh, S.J., Clayden, A.D., et al. (1982) The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry, 141, 518-523.
20. Lehrer, P.M., Woolfolk, R.L. (1982) Self-report assessment of anxiety: Somatic, cognitive, and behavioral modalities. Behav Assess, 4, 167.
21. Sheehan, D.V. (1983) The anxiety disease. Scribner's, New York.
22. Covi, L., Lipman, R.S. (1984) Primary depression or primary anxiety? A possible psychometric approach to a diagnostic dilemma. Clin Neuropharmacol, 7 (s), 501.
23. Beck, A.T., Epstein, N., Brown, G. et al. (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol, 56 (6), 893-897.
24. Thyer B.A. (1992). Clinical Anxiety Scale (CAS). In Hudson W.W. (ed.), The WALMYR Assessment Scale Scoring Manual. WALMYR Publishing Co., Temple, AZ.
25. Geer, J.H. (1965) The development of a scale to measure fear. Behav Res Ther, 3, 45.
26. Marks, I.M., Mathews, A.M. (1979) Brief standard self-rating for phobic patients. Behav Res Therapy, 17, 263.
27. Watson, D., Friend, R. (1969) Measurement of social-evaluative anxiety. J Consult Clin Psychol, 33, 448.
28. Glass, C.R., Merluzzi, T.V., Biever, J.L. et al. (1982) Cognitive assessment of social anxiety: Development and validation of a self-statement questionnaire. Cogn Ther Res, 6, 37.
29. Leary, M.R., Kowalski, R.M. (1983) The Interaction Anxiousness Scale: Construct and criterion-related validity. J Personal Assess, 61, 136.
30. Leary, M.R. (1987) Social anxiousness: The construct and its measurement. J Personal Assess, 47, 66.
31. Liebowitz, M.R. (1987) Social phobia. Mod Probl Pharmacopsychiatry, 22, 141.
32. Davidson, J.R., Potts, N.L., Richichi, E.A., et al. (1991) The Brief Social Phobia Scale. J Clin Psychiatry, 52, 48.
33. Chambless, D.L., Caputo, G.C., Bright, P. et al. (1984) Assessment of fear of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Cons Clin Psychol, 52, 1090.
34. Chambless, D.L., Caputo, G.C., Jasin, S.E. et al. (1985) The Mobility Inventory for Agoraphobia. Behav Res Ther, 23, 35.
35. Pancheri, P. (1995) Approccio dimensionale e approccio categoriale alla nosografia psichiatrica. Ital J Psychopathol, 1, 8-23.
36. Reiss, S., Peterson, R.A., Gursky, D.M. et al. (1986) Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther, 24 (1), 1-8.
37. Clum, G.A., Broyles, S., Borden, J. et al. (1990) Validity and reliability of the Panic Attack Symptoms and Cognition Questionnaire. J Psychopath Behav Assess, 12, 233.
38. Wilkinson, G., Balestrieri, M., Ruggeri, M. et al. (1991) Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders. Psychological Medicine, 21 (4), 991-998.
39. Boyer, W. (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. International Clinical Psychopharmacology, 10, 45-49.
40. van Balkom, A.J., Bakker, A., Spinhoven, P. et al. (1997) A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. The Journal of Nervous and Mental Diseases, 185 (8), 510-516.
41. Bakker, A., van Balkom, A.J.L.M., and Spinhoven, P. (2002) SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatrica Scandinavica, 106, 163-167.
42. Furukawa T.A., Watanabe N., Churchill R. (2007) Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews, 24.
43. Bandelow, B., Seidler-Brandler, U., Becker, A. et al. (2007) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. The World Journal of Biological Psychiatry, 8 (3), 175-187.
44. Ipser, J.C., Carey, P., Dhansay, Y. et al. (2006) Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews 4.
45. Hirschmann, S., Dannon, P.N., Iancu, I. et al. (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 20, 556-559.
46. Kessler, R.C. and Wang, P.S. (2008) The descriptive epidemiology of commonly occurring mental disorders in the United States. Annual Review of Public Health, 29, 115-129.
47. Gorman, J.M. (2003) Treating generalized anxiety disorder. The Journal of Clinical Psychiatry, 64 (Suppl 2), 24-29.
48. Struzik, L., Vermani, M., Coonerty-Femiano, A. et al. (2004) Treatments for generalized anxiety disorder. Expert Review of Neurotherapeutics, 4 (2), 285-294.
49. Rynn, M.A. and Brawman-Mintzer, O. (2004) Generalized anxiety disorder: acute and chronic treatment. CNS Spectrums, 9 (10), 716-723.
50. Rudolph, U. (2001) Identification of molecular substrate for the attenuation of anxiety: a step toward the development of better anti-anxiety drugs. The ScientificWorldJournal, 1, 192-193.
51. Goodman, W.K. (2004) Selecting pharmacotherapy for generalized anxiety disorder. The Journal of Clinical Psychiatry, 65 (Suppl 13), 8-13.
52. Martin, J.L., Sainz-Pardo, M., Furukawa, T.A. et al. (2007) Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology, 21 (7), 774-782.
53. Schmitt, R., Gazalle, F.K., Lima, M.S. et al. (2005) The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Revista Brasileira de Psiquiatria, 27 (1), 18-24.
54. Mula, M., Pini, S., and Cassano, G.B. (2007) The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. Journal of Clinical Psychopharmacology, 27 (3), 263-272.
55. Bandelow, B., Wedekind, D., and Leon, T. (2007) Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Review of Neurotherapeutics, 7 (7), 769-781.
56. Feltner, D., Wittchen, H.U., Kavoussi, R. et al. (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology, 23 (1), 18-28.
57. Stein, D.J., Baldwin, D.S., Baldinetti, F. et al. (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. European Neuropsychopharmacology, 18 (6), 422-430.
58. Mitte, K. (2005) Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychological Bulletin, 131 (5), 785-795.
59. Bagby, R.M. and Quilty, L.C. (2006) Review: cognitive behavioural therapy is more effective than control and similarly effective to pharmacotherapy for generalised anxiety disorder. Evidence-Based Mental Health, 9 (2), 43.
60. Gao, K., Muzina, D., Gajwani, P. et al. (2006) Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. The Journal of Clinical Psychiatry, 67 (9), 1327-1340.
61. Stein D.J., Ipser J.C., Balkom A.J. (2004) Pharmacotherapy for social anxiety disorder. Cochrane Database of Systematic Reviews 4.
62. Fedoroff, I.C. and Taylor, S. (2001) Psychological and pharmacological treatments of social phobia: a meta-analysis. Journal of Clinical Psychopharmacology, 21 (3), 311-324.
63. Hansen, R.A., Gaynes, B.N., Gartlehner, G. et al. (2008) Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. International Clinical Psychopharmacology, 23 (3), 170-179.
64. Hofmann, S.G. and Smits, J.A. (2008) Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. The Journal of Clinical Psychiatry, 69 (4), 621-632.
65. Blomhoff, S., Haug, T.T., Hellström, K. et al. (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. The British Journal of Psychiatry, 179, 23-30.
66. Davidson, J.R., Foa, E.B., Huppert, J.D. et al. (2004) Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry, 61 (10), 1005-1013.
67. Stein, M.B., Sareen, J., Hami, S. et al. (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. The American Journal of Psychiatry, 58 (10), 1725-1727.
68. Dow, B. and Kline, N. (1997) Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Annals of Clinical Psychiatry, 9 (1), 1-5.
69. Ipser, J., Seedat, S., and Stein, D.J. (2006) Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. South African Medical Journal, 96 (10), 1088-1096.
70. Raskind, M.A., Peskind, E.R., Kanter, E.D. et al. (2003) Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. The American Journal of Psychiatry, 160 (2), 371-373.
71. Pae, C.U., Lim, H.K., Peindl, K. et al. (2008) The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology, 23 (1), 1-8.
72. Hamner, M.B., Faldowski, R.A., Ulmer, H.G. et al. (2003) Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. International Clinical Psychopharmacology, 18 (1), 1-8.
73. Tucker, P., Trautman, R.P., Wyatt, D.B. et al. (2007) Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry, 68 (2), 201-206.
74. Lindley, S.E., Carlson, E.B., and Hill, K. (2007) A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 27 (6), 677-681.
75. Mueser, K.T., Rosenberg, S.D., Xie, H. et al. (2008) A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clinical Psychology, 76 (2), 259-271.